Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
- Author(s)
- Dhiantravan, N; Violet, J; Eapen, R; Alghazo, O; Scalzo, M; Jackson, P; Keam, SP; Mitchell, C; Neeson, PJ; Sandhu, S; Williams, SG; Moon, D; Lawrentschuk, N; Azad, A; Hofman, MS; Murphy, DG;
- Details
- Publication Year 2021-03,Volume 7,Issue #2,Page 234-237
- Journal Title
- European Urology Focus
- Publication Type
- Protocol
- Abstract
- LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.
- Keywords
- Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; *Prostatectomy; Prostatic Diseases/*surgery
- Department(s)
- Cancer Imaging; Radiation Oncology; Surgical Oncology; Laboratory Research; Pathology; Medical Oncology
- PubMed ID
- 33172774
- Publisher's Version
- https://doi.org/10.1016/j.euf.2020.09.021
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-01-30 05:59:56
Last Modified: 2026-01-30 06:01:39